New hope for melanoma patients: drug combos show promise before surgery

NCT ID NCT04303169

Completed Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times

Summary

This study tested several experimental drug combinations, given before surgery, for people with stage III melanoma that can be removed. The goal was to see if these combinations are safe and work better than current treatments. About 146 adults took part, receiving different combinations of pembrolizumab with other drugs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

A.P.H. Paris, Hopital Saint Louis ( Site 3107)

Paris, 75010, France
CHUV Centre Hospitalier Universitaire Vaudois ( Site 3602)

Lausanne, Canton of Vaud, 1011, Switzerland
Centre Hospitalier Lyon Sud ( Site 3102)

Pierre-Bénite, Rhone, 69495, France
Chaim Sheba Medical Center ( Site 3701)

Ramat Gan, 5265601, Israel
Duke Cancer Institute ( Site 3005)

Durham, North Carolina, 27710, United States
Fiona Stanley Hospital ( Site 3401)

Murdoch, Western Australia, 6150, Australia
Gustave Roussy ( Site 3101)

Villejuif, Île-de-France Region, 94805, France
HaEmek Medical Center ( Site 3703)

Afula, 1834111, Israel
Hadassah Ein Karem Jerusalem ( Site 3702)

Jerusalem, 9112001, Israel
Hopital La Timone ( Site 3103)

Marseille, Bouches-du-Rhone, 13005, France
Hôpitaux Universitaires de Genève (HUG)-Oncology ( Site 3603)

Geneva, Canton of Geneva, 1211, Switzerland
Inova Schar Cancer Institute ( Site 3011)

Fairfax, Virginia, 22031, United States
Institut Claudius Regaud ( Site 3105)

Toulouse, Haute-Garonne, 31059, France
Istituto Europeo di Oncologia ( Site 3301)

Milan, 20141, Italy
Martha Morehouse Tower ( Site 3020)

Columbus, Ohio, 43221, United States
Melanoma Institute Australia ( Site 3402)

Wollstonecraft, New South Wales, 2065, Australia
NYU Clinical Cancer Center ( Site 3002)

New York, New York, 10016, United States
Oregon Health & Science University ( Site 3013)

Portland, Oregon, 97239, United States
Policlinico Le Scotte - A.O. Senese ( Site 3377)

Siena, 53100, Italy
Providence Saint John's Health Center ( Site 3010)

Santa Monica, California, 90404, United States
Rabin Medical Center-Oncology ( Site 3705)

Petah Tikva, 4941492, Israel
Rambam Health Care Campus-Oncology ( Site 3704)

Haifa, 3109601, Israel
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 3022)

Baltimore, Maryland, 21287, United States
Tasman Oncology Research Pty Ltd ( Site 3403)

Southport, Queensland, 4215, Australia
The Angeles Clinic and Research Institute ( Site 3009)

Los Angeles, California, 90025, United States
Universitaetsspital Zuerich ( Site 3601)

Zuerich Flughafen, Canton of Zurich, 8058, Switzerland
University of Colorado, Anschutz Cancer Pavilion ( Site 3012)

Aurora, Colorado, 80045, United States
University of Pennsylvania Abramson Cancer Center ( Site 3008)

Philadelphia, Pennsylvania, 19104, United States
West Cancer Center - East Campus ( Site 3014)

Germantown, Tennessee, 38138, United States

Conditions

Explore the condition pages connected to this study.

MELANOMA